NasdaqCM - Nasdaq Real Time Price USD

Predictive Oncology Inc. (POAI)

1.1000

-0.0700

(-5.98%)

At close: May 2 at 4:00:00 PM EDT

1.1009

+0.00

+(0.08%)

After hours: May 2 at 7:36:05 PM EDT

Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has made significant progress along the continuum of biomarker discovery, dru

GlobeNewswire 18 days ago

POAI
-5.98%
China announces retaliatory tariffs, U.S. unemployment rises: Morning Buzz

The major averages were sharply lower again near noon, continuing yesterday’s post-tariff slide. China has retaliated with additional tariffs of 34% on all U.S. goods a day after the Trump administration imposed its own sweeping levies. Meanwhile, the latest U.S. jobs data show that nonfarm payrolls rose by a higher-than-forecast 228,000 jobs, though the unemployment rate has ticked higher. Looking to commodities, oil prices are sharply lower due to a planned output increase promised by OPEC+ as

TipRanks 28 days ago

APP

BKNG

GME
Renovaro Provides Update to Definitive Agreement with Predictive Oncology

LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United

GlobeNewswire 29 days ago

RENB

POAI
-5.98%
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

Company continues to progress toward the signing of a definitive merger agreement with RenovaroPITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31

GlobeNewswire last month

POAI
-5.98%
Predictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer Research

We recently published a list of Top 8 AI News Updates Driving Markets Today. In this article, we are going to take a look at where Predictive Oncology Inc. (NASDAQ:POAI) stands against other top AI news updates driving markets today. The AI race switched gears after Chinese AI startup DeepSeek announced on March 25th that […]

Insider Monkey last month

POAI
-5.98%
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive models derived from 21 unique compo

GlobeNewswire last month

POAI
-5.98%
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences PITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has completed the sale of assets related to its wholly owned subsidiary, Skyline Medical Inc

GlobeNewswire last month

POAI
-5.98%
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro’s Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation

GlobeNewswire last month

POAI
-5.98%

RENB
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro’s recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology’s biomarker and drug discovery opportunities and the development of diagnostic applications in oncology Merger expected to enhance shareholder value, accelerate business development efforts and solidify positioni

GlobeNewswire last month

POAI
-5.98%

RENB
Predictive Oncology Closes Registered Direct Offering

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company fr

GlobeNewswire 2 months ago

POAI
-5.98%
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 19, 2025, subje

GlobeNewswire 2 months ago

POAI
-5.98%
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities with meaningful long-term commercial potential with large pharmaceutical companies PITTSBURGH, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today provided an update highlighting new successes with its drug repurposing ini

GlobeNewswire 2 months ago

POAI
-5.98%
Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis

Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids Results presented at the 2025 Society for Laboratory Automation and Screening (SLAS) PITTSBURGH, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from an ongoing study in collaboration with Switzerland-based Tecan, Ltd. were rece

GlobeNewswire 2 months ago

POAI
-5.98%
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States. The ChemoFx® treatment

GlobeNewswire 3 months ago

POAI
-5.98%
Renovaro Issues Shareholder Letter and Provides Corporate Update

Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive anal

GlobeNewswire 3 months ago

POAI
-5.98%

RENB
Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug disco

GlobeNewswire 3 months ago

RENB

POAI
-5.98%
Predictive Oncology Announces Agreement to be Acquired by Renovaro

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’ interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, I

GlobeNewswire 3 months ago

POAI
-5.98%

RENB
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including a potential sale of the Company, a sale of one or more assets of the Company, a merger, licensing agreement, or other strat

GlobeNewswire 4 months ago

POAI
-5.98%
Predictive Oncology Third Quarter 2024 Earnings: Misses Expectations

Predictive Oncology ( NASDAQ:POAI ) Third Quarter 2024 Results Key Financial Results Revenue: US$345.7k (down 52% from...

Simply Wall St. 5 months ago

POAI
-5.98%
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

Company initiates process to explore a broad range of strategic alternatives to maximize shareholder valuePITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended S

GlobeNewswire 5 months ago

POAI
-5.98%

Performance Overview

Return	POAI	S&P 500 (^GSPC)
YTD	+34.15%	-3.31%
1-Year	-35.29%	+12.29%
3-Year	-92.25%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Predictive Oncology Inc. (POAI)

Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

China announces retaliatory tariffs, U.S. unemployment rises: Morning Buzz

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

Predictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer Research

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Predictive Oncology Closes Registered Direct Offering

Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis

Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

Renovaro Issues Shareholder Letter and Provides Corporate Update

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Predictive Oncology Announces Agreement to be Acquired by Renovaro

Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives

Predictive Oncology Third Quarter 2024 Earnings: Misses Expectations

Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

Performance Overview